Rescheduling Is Not Deregulation: FDA and OSHA Risks Ahead for High THC cannabis

Rescheduling high THC cannabis has been widely framed as a win for the industry due to reduced tax burden, increased legitimacy, and a step closer to mainstream acceptance. But there’s a critical detail getting lost in the celebration: Rescheduling is not deregulation.

In many ways, it does the opposite. As high THC cannabis moves out of Schedule I, federal agencies that previously kept their distance, most notably the FDA and OSHA, gain clearer authority to step in. For operators, manufacturers, and brands, this marks the beginning of a very different compliance era.

 

What is The Most Likely Outcome: Schedule III

The most likely rescheduling outcome for high THC cannabis is a move to Schedule III, a classification reserved for substances with an accepted medical use. While often viewed as a step toward deregulation, Schedule III actually provides the FDA with a much clearer path to assert authority.

Once high THC cannabis is no longer classified as Schedule I, the regulatory barriers that limited FDA involvement largely disappear. High THC cannabis products, particularly those resembling drugs, foods, or supplements, are no longer confined to a state only framework. Instead, they fall more squarely under existing federal law. Under Schedule III, the FDA can more readily:

• Evaluate high THC cannabis-derived products as drugs
• Enforce the Food, Drug, and Cosmetic Act
• Take action on unapproved, misbranded, or adulterated products

This shift may not require new high THC cannabis-specific regulations. It may simply allow the FDA to apply authorities it already has setting the stage for significantly expanded federal oversight.

 

FDA: From The Sidelines to the Spotlight

While high THC cannabis remained classified as Schedule I, FDA enforcement was relatively limited and selective. Rescheduling changes that dynamic by moving high THC cannabis closer to pharmaceutical, food, and dietary supplement regulatory models. Once high THC cannabis is acknowledged to have an accepted medical use, the FDA can more directly and consistently apply the Food, Drug, and Cosmetic Act (FD&C Act) to high THC cannabis-derived products, particularly those that resemble drugs, foods, or supplements.

As a result, companies should expect increased FDA scrutiny of:

• Health and therapeutic claims, including those made on labels, websites, and social media
• Edibles and beverages, especially products appealing to consumers or resembling conventional foods
• Labeling accuracy, including potency, serving size, net weight, and implied health benefits
• Manufacturing practices, such as sanitation, process controls, documentation, and recordkeeping

Products that have long operated comfortably under state high THC cannabis programs may suddenly be viewed under federal law as unapproved new drugs or adulterated foods. Historically, the FDA’s first step in these situations is often a warning letter, and those are likely to increase well before any cannabis-specific federal framework is finalized.

Companies should expect warning letters to target not only product labels, but also:

• Company websites
• Social media marketing
• Certificates of Analysis (COAs) used as marketing tools

Past FDA warning letters in the cannabis and hemp space have cited violations such as:

• Disease claims
• Structure/function claims
• Inconsistent or unsupported potency labeling
• Serving size manipulation
• Misleading or implied “medical” branding

If a product makes medical claims (such as pain relief, anxiety reduction, insomnia support, or PTSD treatment), uses defined dosage forms (capsules, tinctures, measured edibles), or is consistently marketed for treatment, the FDA may classify it as an unapproved drug. In those cases, the agency can require companies to pursue the Investigational New Drug (IND) pathway, which may ultimately lead to a New Drug Application (NDA), the same regulatory route used by traditional pharmaceutical products. This is the pathway through which Epidiolex (CBD) entered the U.S. market.

At a high level:

• IND means: “You may now test this drug in people.”
• NDA means: “You have demonstrated this drug is safe, effective, and consistently manufactured.”

The gap between pharmaceutical requirements and most state high THC cannabis regulations is significant. FDA drug oversight includes expectations for stability data, expanded testing requirements, validated analytical methods, adverse event reporting, and strict traceability and recall capabilities; standards many cannabis operators are not yet prepared to meet.

 

OSHA: The Overlooked Federal Risk

FDA isn’t the only agency watching. With many high THC cannabis facilities operating like traditional production facilities (including chemical extraction, food manufacturing, and pharmaceutical production sites), increased OSHA scrutiny should be expected.

Rescheduling strengthens the argument that high THC cannabis workplaces should meet the same expectations as other regulated manufacturing environments and require the same regulatory oversight as any other work environment. Worker safety expectations include:

• Hazard communication
• Solvent exposure controls
• Combustible dust and extraction hazards
• Training, PPE, and written safety programs
• Emergency response

For companies that have relied primarily on state high THC cannabis regulations, OSHA inspections can feel unfamiliar and costly if safety systems aren’t already in place.

 

State Rules Won’t Disappear, But They Might Not Be Enough

Rescheduling does not replace state high THC cannabis programs. Licenses, inspections, and state-specific rules will remain in place. However, companies may expect dual compliance moving forward:

• State high THC cannabis regulations plus
• Federal FDA and OSHA expectations

This is a shift many operators underestimate. Federal agencies are not obligated to align with state tolerance levels when products cross into food, drug, or workplace safety territory.

 

What Smart Operators Are Doing Now

Companies best positioned for this transition aren’t waiting for final rules. They’re already:

• Building GMP systems (documented SOPs, change control, training) leading to GMP certification
• Robustly handling complaints
• Tightening labeling & claims review
• Validating testing methods (not just state-accepted)
• Qualifying suppliers
• Preparing for recalls 
• Reviewing safety practices through an OSHA lens
• Preparing for regulatory inspections

In short, they’re operating like federally regulated manufacturers, not just state licensed high THC cannabis businesses.

 

What about Hemp?

Over the last year there have been some changes so here is a quick breakdown:

1. The federal law redefines what “hemp” means at the federal level

Under the 2018 Farm Bill, hemp was defined as cannabis with no more than 0.3% delta-9 THC by dry weight. That definition allowed a wide range of hemp-derived cannabinoids (like delta-8, delta-10, HHC, THCA, etc.) to be sold legally as long as the delta-9 THC stayed below the limit.

The new bill changes that definition by shifting to a combined total THC standard and narrowing what counts as “hemp.” “Total THC” now includes not just delta-9 but also THCA and other cannabinoids the Secretary of Health and Human Services determines have similar effects. That effectively excludes many products from qualifying as hemp.

2. Most intoxicating hemp-derived products will no longer be legal as “hemp.”

The bill’s new definition excludes:

• Products containing more than 0.3% total THC (including THCA).
• Products containing cannabinoids that are synthesized or manufactured (e.g., many delta-8, delta-10, HHC, and other minor cannabinoids made from extracted CBD).

3. Hemp products with intoxicating potential will be regulated like THC Cannabis

If a product no longer qualifies as hemp under the new definition, because of its cannabinoid content or how it was made, it may be treated the same as federally illegal THC under the Controlled Substances Act. That has huge implications for interstate commerce, manufacturing, and retail.

4. There’s a one-year transition period before this takes effect

The restrictions won’t come into force until about late 2026. That gives hemp businesses time to review the changes, and become complaint with cGMP/FDA and OSHA regulations.

5. CBD and purely non-intoxicating hemp may still be lawful, but the rules tighten

Products that do not contain significant intoxicating cannabinoids (and meet the new total THC limit) may remain legal, but the parameters are much tighter. The bill requires federal agencies like the FDA to publish lists of cannabinoids that are considered naturally occurring and clarify which are prohibited. On top of that, they will most likely require compliance with existing FDA and OSHA regulations.

 

The Bottom Line

Rescheduling may reduce some barriers, but it raises the compliance bar. FDA and OSHA oversight won’t arrive overnight but the direction is clear. For high THC cannabis companies, the question is no longer if federal oversight expands, but how prepared you’ll be when it does.

If you’d like help assessing FDA or OSHA readiness, identifying compliance gaps, or preparing for GMP certification, now is the time to start the conversation.